drugset / Trial / NCT02366637

An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease

NCT02366637 ↗

Phase 2 Terminated 13 enrolled Pfizer
RandomizedCrossoverTriple-blindTreatment

Summary

This study proposes to evaluate the safety and efficacy of PF-03715455 in subjects with moderate to severe Chronic Obstructive Pulmonary Disorder.

Timeline

Start
2015-01
Primary completion
2015-05
Completion
2015-05

Outcome

Outcome not reported

Stopped (Business): “Study terminated on 7 April 2015 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study”

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-03715455 Small molecule 680 ug Inhaled